Basically, hemophilia is serious bleeding disorder as it is inherited from the parents to their offspring, it is a condition in which, an individual’s blood is unable to clot in an appropriate manner due to deficiency or absence of some clotting factor in the blood that sometimes further leads to uncontrolled bleeding which can occur spontaneously. People suffering from hemophilia does not have clotting factor viii in their blood. People with hemophilia are more prone to joint inflammation and compartment syndrome as it favors the seepage of blood and plasma into the joints and other parts of the body where the necessary space is kept for other vital functions.
There are two types of hemophilic condition segmented as hemophilia A and hemophilia B among these two hemophilia is more common around the globe. Due to the presence of only one X chromosome in male they are more prone to hemophilia as compared to females. Hemophilia is less common as compared to hemophilia A and it is occurs due to the absence of clotting factor ix in the blood. Among all the people suffering from hemophilia only 30% of the people have no inherited history of the disease and majority are affected due to the heredity nature of the disorder. Drugs that can affect clotting function in hemophilic condition are such as acetylsalicylic acid (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs), except certain COX-2 inhibitors these drugs should be avoided as they promote thinning of blood and favors fast bleeding.
Revenue growth in the hemophilia A and B therapeutics materials is expected to gain traction in the near future owing to favorable environmental cues in the market such as high birth rate worldwide. Taking in account all options under hemophilia therapeutic materials available in home care settings are majorly the frequently hampering factor in the market. Also, the decision of both professional and patient in selecting the most appropriate material for clotting process. The high prevalence of the disorder is expected to favor the market growth for hemophilia A and B therapeutics in the near future.
One of the favorable treatment for the cure of hemophilia is infusion of factor concentrates within a preferred time interval as the bleeding episode starts. Delays in this infusion may result in prolonged recovery and the requirement of other factor infusions for bleeding control and managing the wellbeing of body joints, muscles and other organs that can be affected by the onset of bleeding. Furthermore, the rate of infusion varies with different products used in the treatment. The number of people suffering from hemophilia is increasing along with the rise in other disorders such as HIV, which in turn is expected to be a support for hemophilia A and B therapeutics market.
However, there are some more factors that impede the market such as the availability of the resources in the home care setting and low awareness in the society. The cost of the best material are projected to hinder the market growth in the near future.
By region, hemophilia A and B therapeutics materials market is segmented into five regions: North America, Latin America, Europe, Asia-Pacific and the Middle East & Africa. North America dominates the global hemophilia A and B therapeutics materials market due to advancement in the type of materials and growth in awareness of the ailment.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/14467
Some of the player in the hemophilia A and B therapeutic market are Arsia therapeutics, Spark Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., Sangamo Therapeutics, Inc.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/14467